Penumbra (PEN) Capital Expenditures Growth (3y) (2017 - 2026)
Penumbra (PEN) Capital Expenditures Growth (3y) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 1.64% |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 8.49% |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 8.89% |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 16.83% |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 1.81% |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 0.84% |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 2.15% |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 7.57% |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Penumbra | 12.48 Bn | 11.87 Bn | 253.41 Mn | 87.71% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 87.71% |
| Dec 31, 2025 | 31.59% |
| Sep 30, 2025 | -85.00% |
| Jun 30, 2025 | 83.37% |
| Mar 31, 2025 | -29.63% |
| Dec 31, 2024 | -30.99% |
| Sep 30, 2024 | 27.94% |
| Jun 30, 2024 | 66.12% |
| Mar 31, 2024 | 13.43% |
| Dec 31, 2023 | 5.44% |
| Sep 30, 2023 | 76.74% |
| Jun 30, 2023 | -26.96% |
| Mar 31, 2023 | -43.98% |
| Dec 31, 2022 | -748.58% |
| Sep 30, 2022 | 57.86% |
| Jun 30, 2022 | -6.08% |
| Mar 31, 2022 | 79.30% |
| Dec 31, 2021 | 268.21% |
| Sep 30, 2021 | 39.22% |
| Jun 30, 2021 | -40.42% |